Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends
XTalks
AUGUST 2, 2023
It is a dipeptidyl peptidase-4 inhibitor that keeps insulin levels stable and reduces the amount of glucose produced by the body. In partnership with Seagen, Sanofi will design, develop and commercialize ADCs for three cancer targets using Sanofi’s proprietary monoclonal antibody technology and Seagen’s proprietary ADC technology.
98 
Let's personalize your content